PH12016501529B1 - Internal liquid agent - Google Patents

Internal liquid agent

Info

Publication number
PH12016501529B1
PH12016501529B1 PH12016501529A PH12016501529A PH12016501529B1 PH 12016501529 B1 PH12016501529 B1 PH 12016501529B1 PH 12016501529 A PH12016501529 A PH 12016501529A PH 12016501529 A PH12016501529 A PH 12016501529A PH 12016501529 B1 PH12016501529 B1 PH 12016501529B1
Authority
PH
Philippines
Prior art keywords
liquid agent
internal liquid
inhibited
pigment
caused
Prior art date
Application number
PH12016501529A
Other versions
PH12016501529A1 (en
Inventor
Masashi Yamamoto
Koji Mochizuki
Hitoshi Inokuchi
Shinichi Mita
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PH12016501529B1 publication Critical patent/PH12016501529B1/en
Publication of PH12016501529A1 publication Critical patent/PH12016501529A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

An internal liquid agent containing ambroxol hydrochloride, a pigment, polyethylene glycol, and optional gallic acid or a derivative thereof,is an internal liquid agent, in which changes in color of the ambroxol hydhrochloride caused by irradiation of light are inhibited, no precipitate is formed, discoloration of the pigment caused by heat is inhibited, and bitter taste of ambroxol hydrochloride is suppressed.
PH12016501529A 2014-02-18 2016-08-03 Internal liquid agent PH12016501529A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014028361 2014-02-18
PCT/JP2015/054207 WO2015125757A1 (en) 2014-02-18 2015-02-17 Internal liquid agent

Publications (2)

Publication Number Publication Date
PH12016501529B1 true PH12016501529B1 (en) 2017-02-06
PH12016501529A1 PH12016501529A1 (en) 2017-02-06

Family

ID=53878259

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501529A PH12016501529A1 (en) 2014-02-18 2016-08-03 Internal liquid agent

Country Status (3)

Country Link
JP (1) JP6372559B2 (en)
PH (1) PH12016501529A1 (en)
WO (1) WO2015125757A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3949184B2 (en) * 1995-06-13 2007-07-25 テイコクメディックス株式会社 Ambroxol hydrochloride aqueous solution
JP2000007561A (en) * 1998-06-18 2000-01-11 Nissho Corp Ambroxol hydrochloride aqueous solution preparation
US20050075403A1 (en) * 2003-10-02 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of inflammation in the pharynx
ITMI20032463A1 (en) * 2003-12-16 2005-06-17 Advance Holdings Ltd AQUEOUS CONCENTRATED AMBROXOL SOLUTION
DE102004021992A1 (en) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topical preparation containing ambroxol

Also Published As

Publication number Publication date
JPWO2015125757A1 (en) 2017-03-30
PH12016501529A1 (en) 2017-02-06
WO2015125757A1 (en) 2015-08-27
JP6372559B2 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
BR112017011972A2 (en) azabicycloctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal disorders
EA201692050A1 (en) TREATMENT OF NON-ALCOHOLIC FATIAL DISEASE OF THE LIVER AND NON-ALCOHOL STEATOGEPATITIS
BR112016018555A8 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS, THEIR USE, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND LSD1 INHIBITION METHOD
BR112016018062A2 (en) therapeutic compounds, pharmaceutical composition and uses
EP3102291A4 (en) Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
GT201700058A (en) 1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-ILO COMPOUNDS AND USES THEREOF
BR112016025396A2 (en) heterocyclyl butanamide derivatives
EP3408254A4 (en) Salts of 5-aminolevulinic acid and derivatives
BR112017008481A2 (en) antimycotic compound
EP3186371A4 (en) Administration of kynurenine depleting enzymes for tumor therapy
EP3442505A4 (en) Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors
EP3515559A4 (en) Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
BR112016028316A2 (en) oral pharmaceutical composition of isotretinoin, its preparation process and treatment method
BR112017008097A2 (en) method for treating eye conditions
BR112015024703A2 (en) pharmaceutical formulation, method of treatment and / or prevention of restenosis and kit for the treatment and / or prevention of restenosis
PH12016502235A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
EP3193870A4 (en) Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
EA201691796A1 (en) N-SUBSTITUTED ASYMMETRIC UREA AND THEIR APPLICATION IN MEDICINE
BR112017028012A2 (en) THERAPY COMBINED WITH AN ANTIBODY-ANTI-HER2 DRUG CONJUGATE AND A BCL-2 INHIBITOR
MX2018003802A (en) Formulation of hypericin for photodynamic diagnosis.
HK1257666A1 (en) Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
PH12016501529B1 (en) Internal liquid agent
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
DOP2016000325A (en) COMPOUNDS, PHARMACEUTICAL COMPOSITION AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
EA201501130A1 (en) OPHTHALMOLOGIC PHARMACEUTICAL COMPOSITION